Dear Animal Care Clinic Family,
We are thrilled to announce that because of the strides we’ve taken to provide the pinnacle of care to your pets, we’ve been selected to be one of the first clinics in the country to offer a new pain management medication to the dogs we care for. We’re so honored to let you know that we can now provide the long-awaited Librela injection, a groundbreaking leap in pain management, poised to profoundly improve the quality of life for dogs grappling with osteoarthritis pain. Thank you for entrusting us with your pet's well-being. We can't wait to share more about Librela and how it can improve the lives of our furry friends.
Sincerely, Animal Care Clinic Team
https://www.librelavetteam.com/for-your-clients
Here's why Librela is a game-changer for dog healthcare:
-Librela is a groundbreaking approach to pain management in dogs, offering long-term control of canine osteoarthritis (OA) pain through a monthly anti-NGF monoclonal antibody injection.
-It effectively controls OA pain with just one monthly injection, providing consistent relief for dogs.Librela works differently compared to NSAIDs (nonsteroidal anti-inflammatory drugs) by targeting and reducing the effects of NGF (nerve growth factor), a key factor in canine OA pain.
-It is approved as safe for use and functions similarly to naturally occurring antibodies, with minimal metabolism by the liver or kidneys.
-Librela has been shown to reduce canine OA pain, resulting in increased activity levels and an overall improvement in the quality of life for dogs.
-Librela is not an experimental medication; it has been commercially available in Europe since 2021, and there exists a wealth of documented data highlighting its substantial impact on enhancing the lives of dogs. Call us today to be among the first to experience the transformative effects of Librela.
https://youtu.be/uzCcQtkrI28?si=3qFlRSD-m1MKuFal
Librela has been positively impacting dogs' lives in Europe and Australia for numerous years. Check out this video showcasing the extraordinary results from this new injection.